Nogo is a potent inhibitor of regeneration following spinal cord injury. To develop a better understanding of the mechanisms responsible for regenerative failure we used a yeast twohybrid approach to try and identify proteins that interact with Nogo. We identified a novel mitochondrial protein designated Nogo-interacting mitochondrial protein (NIMP) in a screen of an adult human brain cDNA library. This interaction was confirmed by co-immunoprecipitation in both brain tissue (endogenous) and transfected HEK293T cells (overexpressed). In support of these studies we demonstrate that Nogo interacts with the UQCRC1 and UQCRC2 components of complex III, within the mitochondrial respiratory chain. The mitochondrial localization of NIMP was evidenced by confocal image analysis and western blot analysis of isolated mitochondria. NIMP is highly conserved and ubiquitously expressed in mitochondria-enriched tissues. Within the CNS, NIMP-like immunoreactivity is present in neurons and astrocytes. These data suggest that NIMP is a novel mitochondrial protein that interacts with Nogo. The interaction of Nogo with mitochondrial proteins may provide insight into the mechanisms for Nogo-induced inhibition of neurite growth.
Axons in the CNS of higher vertebrates generally fail to regenerate after injury. Regenerative failure may be due to the presence of growth inhibitory molecules within CNS myelin (Qiu et al. 2000) . One of these inhibitors, Nogo-A (Schwab and Caroni 1988; Spillmann et al. 1998; Chen et al. 2000) and its cDNA have recently been identified and characterized (Chen et al. 2000; GrandPré et al. 2000; Prinjha et al. 2000) . Recombinant Nogo-A has properties similar to the purified myelin inhibitor NI250. Nogo-A inhibits fibroblast spreading and neurite extension from cerebellar neurons and mature sensory neurons; it is expressed at high levels in myelinating cells from the CNS (oligodendrocytes) but not from the peripheral nervous system (Schwann cells); and it is recognized by a monoclonal antibody, IN-1, raised against NI250 and NI35. IN-1 can induce long-distance neurite regeneration (Cadelli and Schwab 1991; Schnell et al. 1994; Weibel et al. 1994; Brosamle et al. 2000) , compensatory sprouting (Z'Graggen et al. 1998; Buffo et al. 2000) and functional recovery (Merkler et al. 2001; Raineteau et al. 2001) following CNS injury in rats.
However, the mechanism responsible for Nogo-A-induced growth inhibition remains elusive. Nogo-A is largely localized in the endoplasmic reticulum (ER), with only small amounts reaching the surface of oligodendrocytes, suggesting that Nogo-A functions predominantly within cells, at least in the non-injured situation (Chen et al. 2000; GrandPré et al. 2000; Prinjha et al. 2000) . The complicated topology of Nogo-A makes it difficult to understand which portion of the protein causes regenerative failure (Goldberg and Barres 2000; Tessier-Lavigne and Goodman 2000; Brittis and Flanagan 2001) . Using a functional screening approach, Strittmatter and colleagues have identified a receptor (NgR) for the putative extracellular/lumenal domain of Nogo-A [Nogo(ecd)] (Fournier et al. 2001) , further confirming that Nogo(ecd) is on the extracellular membrane surface. However, the N-terminus of Nogo-A may also contribute to the inhibition of neurite growth or regeneration (GrandPré et al. 2000; Fournier et al. 2001) . NgR is attached to the plasma membrane through a GPI linker, suggesting that NgR is a coreceptor (Fournnier et al. 2001) , whereas the transmembrane component of the Nogo receptor that initiates intracellular signaling is yet unknown.
In this study, a yeast two-hybrid screen with the putative Nogo(ecd) as bait was performed to identify proteins that may interact with Nogo. From an adult human brain cDNA library, we identified a core protein of mitochondrial respiratory chain (MRC) complex III, ubiquinol-cytochrome c reductase core protein II (UQCRC2) and a novel mitochondrial protein designated NIMP that interact with Nogo(ecd). The interaction of Nogo with core mitochondrial proteins may explain in part Nogo-induced regenerative failure following spinal cord injury.
Materials and methods
General methods and materials PCR primers were obtained from AlphaDNA (Montreal, Canada) and radioactive materials from Amersham (Piscataway, NJ, USA). Proteinase and phosphatase inhibitors and common reagents were obtained from Sigma (St. Louis, MO, USA). Protein concentrations were determined with the detergent kit from Bio-Rad (Hercules, CA, USA). Anti-Myc monoclonal antibody was obtained from Clontech (Palo Alto, CA, USA), anti-Flag monoclonal antibody from Sigma, anti-cytochrome c monoclonal antibody from BD PharMingen (San Diego, CA, USA) and anti-ubiquinol-cytochrome c reductase core protein I (UQCRC1) monoclonal antibody from Molecular Probe (Eugene, OR, USA).
Yeast two-hybrid screening
The yeast two-hybrid system Matchmaker II from Clontech was performed according to the manufacturer's instructions. The bait encoding the putative extracellular domain (1024-1090 residues) of human Nogo-A, generated by PCR from human KIAA0886 clone (Gift from Kazusa DNA Research Institute, Japan), was inserted in frame into GAL4 DNA binding domain in the yeast expression vector pBridge to produce a construct of pBridge-Nogo(ecd). The yeast strain G1945 was transformed with pBridge-Nogo(ecd) using lithium acetate and selected on leucine-deficient medium. The positive transformants were subsequently transformed with a human brain cDNA expression library fused to the GAL4 transactivator domain in expression vector pACT2. The transformed yeast cells were cultured in the absence of leucine, tryptophan and histidine and in the presence of 10 mM a-amino-1,2,4,triazole (3-AT). Those clones that both grew on triplenutrient-deficient plates and were positive (blue) following the b-galactosidase assay were selected and their plasmids were isolated. PCR products of the positive clones were subcloned into the TA-cloning vector (Invitrogen, Carlsbad, CA, USA) Antibody production A synthesized peptide from the deduced amino acids 102-KRDPLHVKIKGEEFPLTLGRD-122 of human NIMP or 381-REEYADFKPFERVWEVKDSKED-402 of human Nogo-A was used as an immunogen to raise polyclonal antisera in rabbits, and the crude antisera were affinity-purified (Research Genetics). The quality and specificity of the antibody were verified by ELISA, western blot, immunoprecipitation and immunohistochemistry.
Cell cultures, transfections and mitochondrial tracker staining The human embryonic kidney (HEK) 293T cell line or monkey kidney COS-7 cell line were maintained in high glucose Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 100 lg/mL penicillin G and 100 lg/mL streptomycin (Gibco BRL, Rockville, MD, USA). For fluorescent microscopy, cells were seeded on six-well dishes or eight-well plastic chamber slides. For western blot and co-immunoprecipitation experiments, cells were seeded on 10-cm dishes. Cells were transfected the following day by the standard calcium phosphate precipitation. At 24-48 h after transfection, RFP fluorescence was observed under the confocal Axiovert 100M microscope with the LSM 510 scanning module (Carl Zeiss, Thornwood, NY, USA). If necessary, the cells were stained with MitoTracker Green FM (50 nM), as instructed by the manufacture (Molecular Probes).
Co-immunoprecipitation and western blot
Transfected HEK293T cells were solubilized in 1.5 mL of Triton X-100 based lysis buffer containing 20 mM Tris)HCl (pH 7.4), 1% Triton X-100, 1 mM EDTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, 10 lg/mL aprotinin, 10 lg/mL leupeptin and phosphatase inhibitor cocktail I (Sigma) for 40 min at 4°C. The nuclear and cellular debris were cleared by centrifugation at 20 000 g for 20 min at 4°C. The lysates were incubated overnight at 4°C with 0.4 lg antibody or control IgG. The immune complexes were precipitated with Dynal magnetic Protein G (Dynal, Lake Success, NY, USA), washed four times with 0.6 M NaCl lysis buffer, and then eluted by boiling for 5 min in sodium dodecyl sulfate (SDS) sample loading buffer. The eluted proteins were fractionated on SDS)PAGE and transferred to nitrocellulose membrane (BioRad). The precipitated proteins were detected by western blot analysis using enhanced chemiluminescence western blotting detection reagents (Amersham). The total lysates were also resolved by SDS)PAGE and detected by western analysis. Endogenous interaction between Nogo and NIMP was determined using whole brain from a normal adult rat. Tissue was homogenized in 1 : 5 (w/v) lysis buffer and incubated for 40 min at 4°C. The nuclear and cellular debris were cleared by centrifugation at 20 000 g for 20 min at 4°C. The supernatant (2 mg) was immunoprecipitated with NIMP antibody or pre-immune serum and the co-precipitated proteins were detected by western blot analysis with anti-Nogo-A(381-402) polyclonal antibody.
Subcellular fractionation
Crude mitochondria were isolated by centrifugation as described previously (Nakagawa et al. 2000; Li et al. 2001) . Cells were washed with phosphate-buffered saline, rinsed by pipetting, and collected by centrifugation at 1000 g. The cells were re-suspended in 0.32 M sucrose, 50 mM Tris)HCl (pH 8.0), 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 10 lg/mL aprotinin, 10 lg/mL leupeptin and phosphatase inhibitor cocktail I (Sigma), homogenized by 30 strokes in a Dounce homogenizer, and intact cells and nuclei were removed by centrifugation at 1000 g for 10 min. The cleared lysate was then centrifuged at 5000 g for 10 min to obtain pellets of mitochondria (mitochondrial fraction). The supernatant was further centrifuged at 100 000 g for 60 min to separate pellets of microsomes (ER fraction) from soluble proteins (cytosol fraction). The intact cells and nuclei were further lysed with 0.8% NP-40 for 20 min and the pure nuclei were collected at 1000 g for 10 min and resuspended in 50 mM HEPES (pH 7.9), 0.4 M KCl, 0.75 mM MgCl 2 , 0.5 mM EDTA, 12.5% glycerol and protein inhibitors as above. The nuclear extracts were collected by centrifuging at 20 000 g for 10 min. All the procedures were performed at 4°C.
Conventional and confocal immunohistochemistry
Free-floating immunohistochemical staining of frozen sections from brain and spinal cord from normal healthy Wistar rats were performed as described previously (Hu et al. 1999) . Briefly, perfusion-fixed 40 lm sections were permeablized with 0.5% Triton X-100 and blocked with 10% normal goat serum for 30 min and then incubated with human NIMP antiserum overnight at 4°C. The following day, sections were washed with phosphatebuffered saline, and secondary goat anti-rabbit biotinated antibody (1 : 200) was applied for 1 h. The sections were then incubated in ABC compound (Vector Laboratories, Burlingame, CA, USA) followed by 3,3¢-diaminobenzidine staining. Replacement of primary antibody with pre-immune serum showed no staining. Incubation of the primary antibody with the human NIMP peptide (100 lg/mL) abolished all staining.
For double indirect fluorescent immunohistochemistry, the sections were pretreated with blocking solution of 5% normal goat serum, 2% rat serum, and 0.4% Triton X-100 overnight at 4°C. The sections were incubated with the primary NIMP polyclonal antibody at a dilution of 1 : 3000 in blocking solution overnight at 4°C. After washing, the Alexa FluorÒ 488 (green)-linked secondary goat antirabbit antibody (Molecular Probes) 1 : 200 was added for 2 h. Neurons were identified with mouse monoclonal anti-neuronal nuclei (NeuN) (Chemicon International, Temecula, Ca, USA) 1 : 200. Oligodendrocytes were stained with mouse monoclonal anti-RIP antibody (DSHB, Iowa, IA, USA) 1 : 40. Astrocytes were stained with mouse monoclonal anti-glial fibrillary acid protein (Chemicon International) 1 : 600. Microglia were stained with mouse monoclonal anti-OX42 antibody (PharMingen) 1 : 400. The second Alexa FluorÒ 594 (red) secondary goat anti-mouse antibody (Molecular Probes) 1 : 200 in blocking solution was used. Staining specificity was determined by omitting the primary antibody. The multiple fluorescence images were analyzed under the confocal Axiovert 100M microscope with an LSM 510 scanning module (Carl Zeiss).
Northern blot analysis
Tissue-specific expression of NIMP was examined by hybridization of a human multiple tissue Northern blot containing 2 lg poly (A)+ RNA (Clontech) with a 600 bp 32 P-labeled SalI/BamHI digested cDNA fragment from yeast isolated NIMP clone using ExpressHyb hybridization solution. Equal RNA loading was confirmed by subsequent probing of the blot with an a-actin cDNA probe.
Results
Identification and cloning of NIMP From 3 · 10 6 yeast transformants, 98 clones were both HIS and a-galactosidase positive, and were further subjected to PCR analysis and sequence determination. From the 20 sequenced clones, two overlapping and independent clones encode an ORF fused in frame to the GAL4 transactivator domain. Both clones are 1160 bp in size with a long poly(A) tail at the 3¢-end, and a start codon at the 5¢-end, but no stop codon upstream at the N-terminus. This gene was designated NIMP. A database search revealed that no other reported gene is identical to human NIMP, however, seven human EST, two bovine EST and one mouse EST match the fragments of human NIMP. One of the human EST clones (Accession no. AL037647) contains 5¢ sequence upstream of NIMP displaying another start codon with the Kozak consensus sequence for translational start (Kozak 1989 (Kozak , 1999 .
In order to compare the homology and conservation of NIMP among species, a mouse EST clone (Accession no. AI874604) was obtained and sequenced. Mouse NIMP is 1820 bp in size with a start codon and a stop codon upstream at the N-terminus. The untranslated sequences at both 5¢-and 3¢-ends of the mouse NIMP cDNA are longer than that of human NIMP. The complete cDNA sequences of human and mouse NIMP are deposited under GenBank Accession nos: AF336861 and AF336862. To identify the chromosome localization of NIMP, a human genome blast search was performed. Human NIMP cDNA precisely matches 390289-391665 bp of human chromosome 12 working draft sequence (Accession no. NT_009488.1).
Both human and mouse NIMP cDNAs have a similar ORF encoding a protein of the same size (396 amino acid) with a predicted molecular mass of 43.56 kDa. Prediction analysis of protein sorting signals and localization sites using PROSORT (Nakai and Horton 1999) reveals that the N-terminal portion (residues 1-42) of both human and mouse NIMP contains a potential mitochondrial localization signal (MLS) with a predicted cleavage site at RS\TV. This MLS sequence shows 69% identity between human and mouse ( Fig. 1) but no homology to any other reported motif or proteins. A conserved domain database search detected a putative conserved zinc-binding alcohol dehydrogenase domain in both human and mouse NIMP. The C-terminal portion (residues 43-396) shares 20-40% homology with several putative members of the oxidoreductase family from flies, eudicots, actinomycetes, fungi, proteobacteria, yeast and mammals. In mammals (mouse and human), NIMP shares 25% identity to quinone oxidoreductase/zeta-crystallin.
However, there is no homology with known MRC components as well as the known oxidoreductase enzymes such as NAD(P)H:quinone oxidoreductase (NQO1). NIMP is highly conserved at the amino acid level between mouse and human with 86% identity throughout the protein and 98% identity at the oxidoreductase domain (residues 43-396, Fig. 1 ). Amino acid sequence from the bovine NIMP EST (Accession no. BF044936) shares 93 and 90% identity with the corresponding domain of human and mouse NIMP, respectively. Motiff search analysis suggested that human NIMP has six protein kinase C phosphorylation sites, four casein kinase II phosphorylation sites, two cAMP-and cGMP-dependent protein kinase phosphorylaiton sites. There are two N-glycosylation sites and seven N-myristoylation sites and one glycosaminoglycan attachment site. As protein phosphorylation at serine, threonine or tyrosine residues affects a multitude of cellular signaling processes, a network-based NETPHOS 2.0 program (Blom et al. 1999 ) was used to predict the serine, threonine or tyrosine phosphorylation sites. In human NIMP, 9 of 22 serine residues, 3 of 24 threonine residues and 2 of 8 tyrosine residues are predicted to be phosphorylated. In mouse NIMP, 12 of 23 serine, 5 of 26 threonine and 3 of 9 tyrosine residues are targeted for possible phosphorylation (Fig. 1) . Intracellular O-glycosylation is Fig. 1 High conservation between human, mouse and bovine NIMP. The underlined letters indicate the mitochondria localization signal (MLS). The italic and bold letters mean the predicted phosphorylation sites at serine, threonine and tyrosine. The dot above the sequences shows the amino acid differences among species.
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characterized by the addition of N-acetylglycosamine to serine and threonine residues in a protein. This glycosylation may prevent phosphorylation at these sites, a mechanism named Ying-Yang regulation. A Yin-Yang prediction using YINOYANG 1.2 software (Gupta et al. 1999) indicated that human NIMP has seven O-linked glycosylation sites at threonine residues.
Mitochondrial localization of NIMP by confocal image analysis and fractionation
Because NIMP contains a putative MLS at its N-terminus, we wanted to confirm if it is indeed a mitochondrial protein.
To address this issue, we cloned the human NIMP cDNA at the C-terminus into an RFP-tagged mammalian expression vector and performed confocal image analysis. The fluorescence of the NIMP-RFP fusion protein presents a characteristic punctate pattern of mitochondrial localization (Figs 2a  and b) , which resembles the mitochondrial localization of the reported mitochondrial protein UQCRC1 fused with RFP at its C-terminus (Fig. 2c) . The RFP empty vector, by itself, appears in an evenly distributed pattern throughout the cytoplasm (Fig. 2e) . Mitochondrial localization was confirmed by the strict coincidence of NIMP-RFP fluorescence with the MitoTracker Green FM (Figs 2a3 and 2b3) . However, when MLS of NIMP was deleted, the expression pattern was diffuse throughout the cytoplasm (Fig. 2d) .
NIMP's mitochondrial localization is further confirmed by the subcellular fractionation. The crude mitochondria isolated from the HEK293T cells transiently overexpressing NIMPFlag or NIMP-RFP were immunoblotted with anti-NIMP antibody. As shown in Fig. 3 , NIMP is largely located in the mitochondrial portion, consistent with the positive control UQCRC1 and cytochrome c. A small amount of NIMP was also detected in ER and nuclear fraction, even though crosscontamination resulting from the relative impurity of the fractionation by centrifugation could not be ruled out. To obtain maximum purity of the nuclear extracts, the nuclei and cell debris were further cleared up with 0.8% NP-40. The absence of UQCRC1 in the nuclear fraction supports the relatively high purity of the nuclear extracts. As shown in Fig. 3 , cytochrome c is also present in nuclear extract, consistent with previous reports (Nakagawa et al. 2000) . 
Physical interaction of NIMP with Nogo in mammalian cells
To confirm the yeast-two hybrid results of the NIMP interaction with Nogo(ecd), HEK293T cells were cotransfected with NIMP-Flag and Myc-Nogo(ecd) vectors. NIMP was co-immunoprecipitated with an anti-myc antibody and detected by western analysis using an anti-Flag antibody. As shown in Fig. 4(a) , Nogo(ecd) interacts with NIMP but does not interact with the presumed negative control NF-jBinducing kinase (NIK). Also, the full-length and the C-terminal domain (1024-1192 residues) of Nogo-A [Nogo(cd)] interact with NIMP when overexpressed (Fig. 4b) . To test the endogenous interaction between Nogo-A and NIMP, the lysates from rat brain and kidney were used for co-immunoprecipitation and western blot analysis (Fig. 4c) . The endogenous Nogo-A in the brain lysates, but not in the kidney lysates, was co-immunoprecipitated by the anti-NIMP polyclonal antibody. In control experiments, pre-immune serum does not co-immunoprecipitate Nogo-A. To help support our results that Nogo interacts with mitochondrial proteins, we tested another positive yeast two-hybrid clone that encodes a reported mitochondrial protein, human UQCRC2. In the yeast two interaction system, UQCRC2, like NIMP, displays a strong interaction with Nogo(ecd). This interaction is further verified by co-immunoprecipitation and western blot in a mammalian system (Fig. 4d) . Because UQCRC1 is another core protein of ubiquinol-cytochrome c reductase (complex III), we hypothesize that UQCRC1 may also interact with Nogo. Co-immunoprecipitation and western blot analysis for the extracts of HEK293T cells cotransfected with Myc-tagged UQCRC1 and Flag-tagged Nogo(cd) demonstrates that UQCRC1 interacts physically with Nogo(cd) although this interaction seems weaker than that between UQCRC2 and Nogo (Fig. 4d ). These data demonstrate that Nogo interacts physically with mitochondrial proteins within complex III.
Tissue distribution of human NIMP mRNA and protein expression Northern blot analysis of human adult tissues reveals that human NIMP is expressed highly in skeletal muscle, heart and kidney, with moderate expression in liver, brain and placenta. Low or no expression is detected in colon, small intestine, lung and immune organs (spleen, thymus and peripheral blood leukocytes). A single transcript is detected with a size of 1.5 kb, equal to the full-length cDNA of human NIMP (Fig. 5a ). An equal amount of mRNA was demonstrated by Northern blot analysis with a-actin (Fig. 5a ).
Western blot analysis with an affinity-purified antibody raised against the deduced polypeptides of human NIMP for HEK293T cells transiently overexpressing NIMP-RFP or NIMP-Flag presents a band of right size as predicted and evidenced by anti-Flag immunoblotting (Figs 3 and 4) , attesting the specificity of the anti-NIMP antibody. Western blot analysis for rat tissues indicates that NIMP protein is expressed in a pattern similar to that of mRNA expression (Fig. 5b) . The same blot after stripping was reprobed with anti-Nogo-A-specific antibody to address whether Nogo-A is coincident with NIMP in tissue distribution. As shown in Fig. 5(b) , NIMP and Nogo-A are colocalized in CNS, heart and kidney but not in liver, spleen, lung and small intestine.
Cellular distribution in CNS
To define the cellular localization(s) of NIMP in the CNS, conventional immunohistochemistry (Fig. 6 ) and double immunofluorescent confocal image analysis (Fig. 7) were performed with an affinity-purified anti-NIMP antibody and different cell-specific markers. In the spinal cord, the NIMPlike reactive staining is distributed primarily in laminae I, II, IV, V, VII and motoneurons (Figs 6a)c) . In the cerebral cortex, the staining is mainly localized to laminae III-V (Figs 6d and e) . In the hippocampus, the prominent staining is observed in pyramidal cells (Figs 6f and g ). In cerebellum, Purkinje cells are intensely stained and some scattered basket cells in the molecular layer are also positive (Figs 6h and i) . The NIMP-like immunoreactivity is colocalized with neuronal marker NeuN and astrocyte marker GFAP but not with oligodendrocyte marker RIP and microglia/microphage marker OX-42 (Fig. 7) . The staining is variable in intensity in most neurons and largely confined to the perikaryon. The staining is also present in the nucleus of large motoneurons (Figs 6c and 7) , which is consistent with the NIMP presence in nuclear fraction (Fig. 4) .
Discussion
This study describes the molecular cloning, tissue distribution, cellular and subcellular localization of a novel mitochondrial protein, NIMP. NIMP is expressed in most tissues and within neurons and astrocytes in the CNS. Nogo interacts with NIMP and this interaction may represent a new additional function of Nogo.
Mitochondrial pre-proteins are synthesized in the cytosol carrying targeting information that is recognized by specific trafficking proteins. In this study, we discovered a novel gene encoding a typical mitochondrial preprotein, NIMP. The following data support this conclusion. (i) Computer-based analysis predicted that both human and mouse NIMP have an N-terminal mitochondrial targeting signal and a cleavage site at RS\TV.
(ii) Confocal image analysis and immunoblot analysis of subcellular fraction confirmed the mitochondrial localization of NIMP.
(iii) Deletion of the N-terminal targeting signal abolished the sorting of NIMP into the mitochondria.
(iv) Nogo also interacts with the mitochondrial proteins UQCRC2 and UQCRC1 of MRC complex III.
Nogo-A is an important myelin inhibitor of axonal growth (Chen et al. 2000; GrandPré et al. 2000; Prinjha et al. 2000) . However, the signaling pathways for Nogo's function are totally unclear. Nogo may have additional functions besides its nerve growth inhibition. Nogo expression is not only restricted in oligodendrocytes but also in neurons (Chen et al. 2000; Josephson et al. 2001 ) and astrocytes (Woodhams et al. 2001 ). Nogo's tissue distribution is not confined to the CNS but is also found in peripheral tissues ( Fig. 5b ; Li et al. 2001) . In this study, we demonstrate that Nogo interacts with two known and one novel mitochondrial protein. First, the yeast two-hybrid screen identified NIMP and UQCRC2 through physical interactions with Nogo(ecd). Second, these interactions were further confirmed by co-immunoprecipitation and western blot analysis in mammalian cells (overexpressed) and brain tissues (endogenous). To confirm Nogo's interaction with mitochondrial proteins at complex III, another core protein of MRC complex III Fig. 6 Photomicrograph depicting expression of endogenous NIMP in the CNS of normal adult rat. Cryostat-cut sections of spinal cord (a)c), cerebral cortex (d and e), hippocampus (f and g) and cerebellum (h and i) were stained with affinity-purified NIMP polyclonal antibody, and the antigenantibody complex was detected by ABC kit with DAB as chromagen. Scale bar ¼ 50 lm.
(UQCRC1) was also tested. Co-immunoprecipitation and western blot analysis following transient overexpression in HEK293T cells demonstrated that UQCRC1 indeed interacts physically with Nogo(ecd). Therefore, Nogo may interact with mitochondrial proteins within MRC complex III. The coincident distribution of NIMP and Nogo in neurons and peripheral tissues also support Nogo's interaction with NIMP. Nogo is primarily located in oligodendrocytes. However, it has been reported that Nogo is also in neurons but to a lesser degree (Chen et al. 2000; Josephson et al. 2001) . The colocalization of Nogo and NIMP in neurons may account for some of Nogo's growth inhibitory properties. Future studies will focus on identifying a function for NIMP and determining if Nogo/NIMP interaction participates in the growth inhibitory properties of Nogo.
Nogo-A is an integral membrane protein with two long transmembrane domains and three additional short hydrophobic stretches at the N-terminus (Chen et al. 2000) . The topology of Nogo-A predicts that the loop between the two long transmembrane domains is on the ER lumen or extracellular side of plasma membrane. It's reasonable that Nogo interacts with mitochondria proteins as such a loop might also be on the matrix side of mitochondria. We are currently investigating the mitochondrial localization or translocation of Nogo to the mitochondria. Another possible explanation is that this interaction would occur when the cells are damaged. Following spinal cord injury, Nogo may be inappropriately targeted to the mitochondria where it binds to specific proteins (NIMP, UQCRC1 and UQCRC2) and destabilizes mitochondrial function. Although we have not been able to demonstrate the mitochondrial colocalization of Nogo with NIMP or other mitochondrial proteins, we have demonstrated that Nogo interacts with NIMP in isolated CNS extracts. In any case, this interaction could occur under pathological conditions such as spinal cord injury or traumatic brain injury. One interesting possibility is that we may be able to partially overcome regenerative failure by enhancing the metabolic potential of neurons.
